ICD-10代码K76.82在肝硬化患者肝性脑病中的诊断效能
本研究在2个大型医疗系统中评估ICD-10代码K76.82对肝性脑病的诊断准确性,并与乳果糖、利福昔明及K72.90比较,共分析2483例患者。联合术语「乳果糖或利福昔明」的敏感性最高,超过98%,而K76.82在所有队列中特异性均超过87%。作者认为K76.82虽有前景,但联合术语能更准确地识别肝性脑病患者。
要点
- 联合术语「乳果糖或利福昔明」识别肝性脑病的敏感性最高,超过98%。
- K76.82在所有队列中的特异性均超过87%。
- 作者认为K76.82虽有前景,但联合术语识别肝性脑病更准确。
核心结论
- K76.82对肝性脑病具有前景,但联合术语「乳果糖或利福昔明」能更准确地识别肝性脑病患者。
研究设计与样本
- 在2个大型医疗系统中评估ICD-10代码K76.82对肝性脑病的诊断效能,并与乳果糖、利福昔明及K72.90比较,共分析2483例患者。
主要发现
- 联合术语「乳果糖或利福昔明」的敏感性最高,超过98%。
- K76.82在所有队列中的特异性均超过87%。
关键数值与推荐
- K76.82对肝性脑病的诊断效能以敏感性、特异性、阳性预测比和阴性预测比评估,对照乳果糖、利福昔明及K72.90。
临床怎么用
- 作者认为K76.82虽有前景,但联合术语「乳果糖或利福昔明」识别肝性脑病更准确。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hepatic encephalopathy (HE) is prevalent and is associated with increased morbidity and mortality among patients with cirrhosis. On October 1, 2022, a new, specific International Classification of Diseases-10 code for HE, K76.82, was introduced. We aimed to analyze the diagnostic accuracy of K76.82. METHODS: Diagnostic performance of K76.82 for HE (sensitivity, specificity, positive predictive ratio, and negative predictive ratio) was evaluated in 2 large health systems compared with lactulose, rifaximin, and K72.90. RESULTS: A total of 2,483 patients were analyzed. The combination term "lactulose or rifaximin" showed the highest sensitivity of >98% while K76.82 demonstrated a specificity of >87% in all cohorts. DISCUSSION: Although K76.82 is promising, the combination term "lactulose or rifaximin" identified patients with HE more accurately.
引用
- Ozturk NB, Jamil LH, Tapper EB, et al. Diagnostic Performance of the ICD-10 Code K76.82 for Hepatic Encephalopathy in Patients With Cirrhosis. Am J Gastroenterol. 2023. PMID: 37830544. doi:10.14309/ajg.0000000000002560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。